DRMA vs. PBLA, CMRA, INM, QLGN, GLMD, LSDI, GRI, BPTH, CMND, and HSTO
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Panbela Therapeutics (PBLA), Comera Life Sciences (CMRA), InMed Pharmaceuticals (INM), Qualigen Therapeutics (QLGN), Galmed Pharmaceuticals (GLMD), Lucy Scientific Discovery (LSDI), GRI Bio (GRI), Bio-Path (BPTH), Clearmind Medicine (CMND), and Histogen (HSTO). These companies are all part of the "pharmaceutical preparations" industry.
Panbela Therapeutics (NASDAQ:PBLA) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by insiders. Comparatively, 9.4% of Dermata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Panbela Therapeutics had 2 more articles in the media than Dermata Therapeutics. MarketBeat recorded 2 mentions for Panbela Therapeutics and 0 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 0.00 equaled Panbela Therapeutics'average media sentiment score.
Panbela Therapeutics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Panbela Therapeutics received 14 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 69.23% of users gave Panbela Therapeutics an outperform vote while only 44.44% of users gave Dermata Therapeutics an outperform vote.
Dermata Therapeutics is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
Panbela Therapeutics currently has a consensus target price of $500.00, indicating a potential upside of 118,947.62%. Given Dermata Therapeutics' higher probable upside, analysts plainly believe Panbela Therapeutics is more favorable than Dermata Therapeutics.
Panbela Therapeutics' return on equity of -107.95% beat Dermata Therapeutics' return on equity.
Summary
Panbela Therapeutics beats Dermata Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dermata Therapeutics Competitors List
Related Companies and Tools
